Agrin and Perlecan Mediate Tumorigenic Processes in Oral Squamous Cell Carcinoma

Rebeca Kawahara1, Daniela C. Granato1, Carolina M. Carnielli1, Nilva K. Cervigne2, Carine E. Oliveria2, César A. R. Martinez1, Sami Yokoo1, Felipe P. Fonseca2, Marcio Lopes2, Alan R. Santos-Silva2, Edgard Graner2, Ricardo D. Coletta2, Adriana Franco Paes Leme1*

1. Laboratório de Espectrometria de Massas, Laboratório Nacional de Bicâncias, LNBio, CNPEN, Campinas, Brazil, 2. Faculdade de Odontologia de Piracicaba, Universidade Estadual de Campinas, UNICAMP, Piracicaba, Brazil

*adriana.paesleme@lnbio.cnpem.org.br

Abstract

Oral squamous cell carcinoma is the most common type of cancer in the oral cavity, representing more than 90% of all oral cancers. The characterization of altered molecules in oral cancer is essential to understand molecular mechanisms underlying tumor progression as well as to contribute to cancer biomarker and therapeutic target discovery. Proteoglycans are key molecular effectors of cell surface and pericellular microenvironments, performing multiple functions in cancer. Two of the major basement membrane proteoglycans, agrin and perlecan, were investigated in this study regarding their role in oral cancer. Using real time quantitative PCR (qRT-PCR), we showed that agrin and perlecan are highly expressed in oral squamous cell carcinoma. Interestingly, cell lines originated from distinct sites showed different expression of agrin and perlecan. Enzymatically targeting chondroitin sulfate modification by chondroitinase, oral squamous carcinoma cell line had a reduced ability to adhere to extracellular matrix proteins and increased sensitivity to cisplatin. Additionally, knockdown of agrin and perlecan promoted a decrease on cell migration and adhesion, and on resistance of cells to cisplatin. Our study showed, for the first time, a negative regulation on oral cancer-associated events by either targeting chondroitin sulfate content or agrin and perlecan levels.
Introduction

Head and neck cancers are the sixth most common malignancy in the world, accounting for more than 500,000 new cases every year [1]. Oral squamous cell carcinoma (OSCC) is the most prevalent cancer occurring in this area [2]. Despite advancements in prevention and multimodality treatments, oral cancer is still characterized by poor prognosis and a low survival rate [3–5].

Long-standing as well as recent data implicate tumor extracellular matrix (ECM) as a significant contributor to tumor progression [6, 7]. However, the entire process orchestrated by interactions between cancer cells and ECM remains poorly understood. One of the major constituents of the ECM, the proteoglycans (PGs), is markedly altered during malignant transformation and tumor progression. Their role is associated with a number of tumorigenic processes, including control of cell growth and survival, induction of apoptosis, adhesion, and invasion [8–10]. Among the main heparan sulfate PGs (HSPG), identified in basement membrane, are agrin and perlecan, which not only were reported to be overexpressed in some cancers, such as prostate cancer [11], hepatocellular carcinoma [12] and breast cancer [13], but also had their function associated with tumorigenic events [10, 14, 15]. Though, no evidence was reported regarding their role in oral cancer.

Perlecan is a large proteoglycan (400–500 kDa) harboring five distinct structural domains, to which long chains of heparan sulfate and/or chondroitin sulfate are attached [16]. This molecule is present in all vascularized tissues with a distribution that is primarily confined to basement membranes [17, 18]. Also, other studies have also identified perlecan in the stromal spaces of various pathophysiological conditions [19–21].

Agrin shares a rather intriguing multimodal organization with perlecan, but more complexity to agrin can be added due to at least four sites of alternative splicing [22]. The amino acid sequence of agrin encodes a protein with a molecular size of 220 kDa, but the observed molecular weight is around 400 kDa due to the long heparan sulfate (HS) and chondroitin sulfate (CS) glycosaminoglycans (GAGs) attached to the core protein [23]. Although originally discovered in the neuromuscular junctions, agrin has been observed in numerous other tissues, and it is described as highly expressed in hepatocellular carcinomas [12, 24, 25] and cholangiocellular carcinomas [12, 24]. Nevertheless, little is known about its role at locations other than the neuromuscular junctions, and even less information is known about its role in tumor tissues.

In the present study, we focused on understanding the role of the proteoglycans agrin and perlecan in oral cancer. First, we sought to validated the overexpression of agrin and perlecan in oral cancer tissues compared to normal tissues and in cell lines with different site of origin: oral squamous carcinoma originated from human tongue (SCC-9), oral squamous carcinoma SCC-9 isolated from lymph nodes (SCC-9 LN-1) and a skin-derived squamous carcinoma (A431). Next, we showed that oral squamous carcinoma cell line had a reduced ability to adhere to extracellular matrix proteins and increased sensibility to cisplatin when treated
with chondroitinase. By specific target agrin and perlecan protein levels with siRNA, we showed that OSCC cells have decreased cell adhesion and migration and increased sensibility to cisplatin treatment. Overall, our findings opened new avenues to better understand the role of agrin and perlecan, as well as their involvement in carcinogenesis, which may offer a novel approach to cancer therapy by targeting the tumor microenvironment.

Materials and Methods

Cell culture

SCC-9 cells (a tumor cell line originated from a human tongue squamous cell carcinoma) were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM/Ham’s F12 medium (Cultilab), supplemented with 10% fetal bovine serum (FBS), antibiotics and 0.4 μg/ml hydrocortisone.

Metastatic oral squamous cell carcinoma (SCC-9) cells were isolated from lymph nodes (LN-1) originating the cell line SCC-9 LN-1 [26] and cultured as recommended for SCC-9. Human epidermoid carcinoma, A431, were grown in Roswell Park Memorial Institute (RPMI) −1640 medium supplemented with 10% FBS and antibiotics. All cell lines were maintained at 37°C in a 5% CO₂ atmosphere.

Analysis of mRNA Expression levels

Fresh-frozen OSCC samples (n=16) and normal oral mucosa (n=16) were used for perlecan and agrin mRNA levels quantification, using qRT-PCR. All patients and volunteers enrolled signed a formulary stating their awareness and consent for the study, approved by the Research Ethics Committee of Faculdade de Odontologia de Piracicaba, Universidade Estadual de Campinas, UNICAMP, Piracicaba, Brazil. Clinical pathological data, such as sex, age, anatomical site of the primary tumor, clinical stage and histopathological grade were collected from patient’s charts and showed in S1 Table. Brief, total mRNA was isolated from fresh-frozen tissue samples using mirVana miRNA Isolation Kit (Ambion), according to the manufacturer’s protocol. First-strand cDNAs were synthesized from 2μg of DNase-treated total RNA using the SuperScript II Reverse Transcription Kit (Invitrogen, Carlsbad, CA, USA). Briefly, diluted cDNA product (1:3) was used to perform a quantitative reverse-transcription polymerase chain reaction (qRT-PCR) using SYBR Green PCR Master Mix (Applied Bios stems) in a 7900 Real-Time PCR System (Applied Biosystems, Foster, CA, USA). The following primers were used to determine mRNA expression levels: Perlecan forward 5’- AAT GCGCTGGACACATTCG-3’ and reverse 5’- ATTCACAGGGCTCGGAAATA-3’; Agrin forward 5’TTGTGCAGTACCTCAACGCT-3’ and reverse 5’- CAGGCTCAGTTCAAAGTCGT-3’. PPIA (cyclophilin A) was used as the
reference gene, forward 5’ GCTTTGGGTCCAGGAATGG 3’ and reverse 5’ GTTGTCACAGTCAGCAATGGT 3’. The PCR cycles were 95˚C for 10 minutes, followed by 40 cycles of 95˚C for 15 seconds and 60˚C for 1 minute. Each reaction was performed in triplicate and analyzed individually. The results were calculated using $2^{-\Delta\Delta Ct}$ relative quantification method; relative quantification was normalized to the pooled normal oral tissues, used as reference control.

For analysis of mRNA expression levels in A431, SCC-9 LN-1 and SCC-9 cell lines, total RNA was obtained using the TRIzol reagent (Invitrogen Corporation) and 2 μg of total RNA were used for retro-transcription using a First-Strand cDNA Synthesis Kit (GE Healthcare). Real-time quantitative PCR for agrin and perlecan was performed using the SYBRH Green PCR Master Mix (Applied Biosystems), and the dissociation curves were performed to confirm the specificity of the products. The threshold cycle (CT) values of the targeted gene were normalized relative to glyceraldehyde-3-phosphate dehydrogenase gene, and relative expression ratios were calculated using the $2^{-\Delta\Delta Ct}$ method. Two independent experiments were performed with triplicates.

**Immunohistochemistry**

High density tissue microarrays were obtained from Biomax (OR601a). The presence of agrin was analyzed in 10 cancer-adjacent normal tissues and in 47 primary oral squamous cell carcinomas by immunohistochemistry using the streptavidin-biotin peroxidase complex (Dako). Protein quantification was assessed with the aid of Aperio Scanscope CS Slide Scanner and the Pixel Count V9 algorithm software (Aperio Technologies, Vista, CA; USA). By using specific input parameters, the percentage of cytoplasm positivity was calculated and classified as weak, moderate and strong, according to its staining intensity. Each category received an intensity score, 1 to weak, 2 to moderate and 3 to strong staining. The final score of each tissue sample was calculated as the sum of the percentage of each category multiplied by their respective intensity scores as the following formula: Score = (%weak × 1)+(%moderate × 2)+(%strong × 3).

Clinical pathological data, such as sex, age, anatomical site of the primary tumor, clinical stage and histopathological grade were collected from patient’s charts and showed in S2 Table.

**Chondroitinase treatment**

Chondroitinase ABC from Proteus vulgaris (Sigma) was reconstituted in a 0.01% bovine serum albumin (BSA) aqueous solution to a final concentration of 6 U/ml. The treatment was performed by diluting the stock chondroitinase in serum free media to a final concentration of 0.1 U/ml for 4 h at 37˚C. After treatment, SCC-9 LN-1 cell lines were submitted to adhesion and migration assays.
In vitro cell migration and adhesion assays

SCC-9, SCC-9 LN-1 or A431 cells, transfected with control siRNA (scramble, sc-44510, Santa Cruz) or specific siRNA against agrin (sc-29652, Santa Cruz) or perlecan (sc-44010, Santa Cruz), were submitted either to cell migration or adhesion assays. Briefly, $3 \times 10^5$ cells were plated in 6 well-plate and, after 24 h, the oligoribonucleotides were transfected with lipofectamine 2000, according to the manufacturer (Invitrogen).

For the in vitro cell migration assay, cells were harvested after 72 h, plated in the upper chambers of the transwell (HTS Transwell 96-Well Plate, Corning), and allowed to migrate towards the lower chamber containing RPMI medium supplemented with 1% FBS for 16 h. At the end of the assay, the non-migrated cells at the top chamber were removed using a cotton swab, and the cells at the bottom of the insert filter were fixed with 10% formaldehyde for 10 min, followed by PBS washing and then staining with 1% toluidine blue solution in 1% borax, for 5 min. The dye was eluted using 1% SDS, and the absorbance of stained cells was measured at 620 nm. Three independent experiments were performed in triplicates.

SCC-9, SCC-9 LN-1 or A431 siRNAs-transfected cells were also submitted to cell adhesion assay, as described by Araújo et al [27]. After 72 h, cells were seeded in a 6-well plate ($2 \times 10^5$) and incubated for 24 h. Then, were washed twice, incubated in serum-free media for 4 h, and seeded in a Matrigel (2 µg per well; BD Biosciences) coated 96-well plate, previously three times PBS-washed and blocked with 3% BSA during 2 h. The adhesion was evaluated during 1 h in serum-free media supplemented with 3% BSA. The wells were washed 3 times, and cells fixed with 10% formaldehyde. Cells were then stained with toluidine blue solution, and absorbance measured at 620 nm, as described above. Three independent experiments were performed with three replicates.

In vitro viability assay

SCC-9, SCC-9 LN-1 or A431 siRNA-transfected cells (scramble, Agrin or Perlecan) were seeded onto 96-well plates and incubated at 37°C/5%CO₂ for two days. MTT (12 mM tetrazolium 3-(4,5- dimethylthiazol-2)-2,5-diphenyltetrazolium bromide) was added, and cells were kept at 37°C for 4 h, in the dark. The media was removed, and 100 µl of 1 N HCl/isopropanol (1:25) was added into each well, followed by gentle agitation at room temperature for 15 min. Finally, the absorbance was measured at 595 nm. Three independent experiments were performed in triplicates.

Drug Sensitivity Assay (MTT)

Cisplatin [cis-diammineplatinum(II) dichloride] (Sigma-Aldrich) was dissolved in 0.150 M NaCl. Aliquots were stored at −20°C for up to a maximum of three months, and thawed immediately before use.
Cells (1 x 10^4) were seeded in 96-well plates and allowed to adhere overnight at 37˚C. Briefly, following treatments of cells with cisplatin (0; 1; 5; 7.5; 10; 25; 50; 100 μM) for 48 h, MTT reagent [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was added to each well, and incubated for 4 h at 37˚C, in the dark. The media were removed, 100 μl of 1 N HCl/isopropanol (1:25) was added in each well, and incubated for 15 min at room temperature under gentle agitation. Finally, absorbance was measured at 595 nm. Three independent experiments were performed in triplicates.

Statistical Analysis
Statistical analysis of gene expression validation by qRT-PCR and immunohistochemistry was performed using the non-parametric Kruskal-Wallis followed by Dunn’s test and Mann-Whitney U test, respectively. For the functional assays adhesion, migration and proliferation, Student’s t-test or ANOVA followed by Tukey’s test was used; p-values<0.05 were set as statistically significant. For drug sensitivity assay, a nonlinear regression curve fit (one phase exponential decay) was used to analyze cisplatin dose response experiments and determine the IC50. All the statistical analysis for mRNA expression analysis and functional assays were performed in GraphPad Prism v6.01.

Results
Agrin and Perlecan are up-regulated in OSCC samples
We started this study by evaluating the mRNA levels of agrin and perlecan, using qRT-PCR in an independent cohort of OSCC samples and normal oral mucosa. Higher expression levels of agrin and perlecan were observed in OSCC samples compared to controls (Fig. 1A, n=16, Kruskal-Wallis followed by Dunn’s test, p<0.05, S1 Table).

We also performed immunohistochemistry analysis in commercial tissue microarrays containing 10 cancer-adjacent normal tissues and 47 primary OSCCs. Normal epithelial cells showed weak reactivity for the antibody against agrin, but a broad positivity was found in the neoplastic cells. Furthermore, there was a significantly higher expression of agrin in tumor samples, compared to controls (S1 Figure, Mann-Whitney U test, p<0.0005, S2 Table).

The mRNA levels of agrin and perlecan were evaluated in cell lines with different sites of origin: oral squamous carcinoma cell line (SCC-9) isolated from tongue, oral squamous carcinoma cell line (SCC-9) isolated from lymph nodes (SCC-9 LN-1) and a skin-derived squamous carcinoma (A431). Whereas the mRNA levels of agrin were higher in SCC-9, the mRNA levels of perlecan were higher in metastatic SCC-9 LN-1 cell lines. A431 showed an intermediary expression for both agrin and perlecan (Fig. 1B/C).
Targeting chondroitin sulfate modification reduced the ability of SCC-9 LN-1 cells to adhere to extracellular matrix and decreased the cell resistance to cisplatin.

To further understand the general role of chondroitin sulfate post-translational modification in tumorigenic processes such as cell adhesion and migration, SCC-9 LN-1 cells were treated with 0.1 U/ml of chondroitinase for 4 h in serum free media, and evaluated for the ability of these cells to adhere to ECM proteins (Matrigel) and migrate. We showed that SCC-9 LN-1 cells treated with chondroitinase had lower ability to adhere to ECM proteins compared to the control (Fig. 2A, n=3, Student’s t-test, p<0.05), whereas no significant effect was observed in the migration of SCC-9 LN-1 cells treated with chondroitinase (Fig. 2B, n=3, Student’s t-test, p>0.05).
Considering previous studies demonstrated the function of heparan sulfate modifications in drug uptake [28], we also evaluated the effect of chondroitinase treatment in the cisplatin cell resistance calculated by the IC50. For that, viability of the SCC-9, SCC-9 LN-1 and A431 cells were determined in the absence (vehicle) or presence of 1, 5, 7.5, 10, 25, 50 or 100 μM of cisplatin. The same curve was constructed with the addition of 0.1 U/ml of chondroitinase. The IC50 of SCC-9 LN-1, SCC-9 and A431 was 36.31 μM, 21.5 μM and 8.24 μM, respectively. When chondroitinase was added, SCC-9 LN-1, SCC-9 and A431 cell lines exhibited a drop in the IC50 (25.62 μM for SCC-9 LN-1, 16.88 μM for SCC-9 and 4.52 μM for A431), decreasing resistance to cisplatin in about 1.5, 1.3 and 1.8 fold for SCC-9 LN-1, SCC-9 and A431 cells, respectively (Fig. 2C).

Fig. 2. Treatment with chondroitinase ABC decreased SCC-9 LN-1 cell adhesion to extracellular matrix, but not SCC-9 LN-1 cell migration and increased sensibility of SCC-9 LN-1, SCC-9 and A431 cells to cisplatin. (A) SCC-9 LN-1 had a lower ability to adhere to extracellular matrix proteins (Matrigel) after treatment with 0.1 U/ml of chondroitinase for 4 h/37°C in serum free media (n=3, triplicate, Student’s t-test, * indicates p<0.05). (B) SCC-9 LN-1 was treated with 0.1 U/ml for 4 h/37°C in serum free media were seeded in the upper chamber of 96-well transwell plates (n=3, triplicate). RPMI media, which was supplemented with 1% FBS, was added in the lower chamber. (C) SCC-9 LN-1, SCC-9 and A431 cells treated with increasing concentrations of cisplatin (0–100 μM) for 48 h in the presence of 0.1 U/ml of chondroitinase showed increased sensibility to cisplatin, calculated by a non-linear regression of a dose-response curves (log[μM cisplatin] vs normalized response). Data are expressed as means ± SD from one independent experiment.

doi:10.1371/journal.pone.0115004.g002
Expression-associated phenotype of agrin and perlecan in adhesion, migration and proliferation event

In order to investigate the role of agrin and perlecan in oral carcinogenesis, we first evaluated the ability of the cells to adhere to extracellular matrix proteins. First, SCC-9, SCC-9 LN-1 and A431 cells lines were scramble-siRNA, agrin-siRNA or perlecan-siRNA transfected, and knockdown of agrin and perlecan were confirmed by qRT-PCR (S2 Figure). We observed that targeted agrin knockdown decreased the adhesion of SCC-9 and SCC-9 LN-1 cells to the Matrigel (Fig. 3A and B, n=3, Student’s t-test, p<0.05), but no significant effect was observed for agrin knockdown in A431 cells. The knockdown of perlecan decreased the adhesion of SCC-9 LN-1 and A431 cells (Fig. 3C and D, n=3, Student’s t-test, p<0.05), but no significant effect was observed for perlecan knockdown in SCC-9 cells.

The role of agrin and perlecan in cell migration was determined using transwell chamber. First, SCC-9, SCC-9 LN-1 and A431 cells treated with control siRNA (scramble) and siRNA against agrin or perlecan were plated in the upper chambers, and allowed to migrate towards the lower chamber containing medium supplemented with 1% FBS. For agrin silenced cells, migration was significantly diminished in SCC-9, SCC-9 LN-1 and A431 cells compared to scrambled control (Fig. 4A–D, n=3, Student’s t-test, p<0.001). For perlecan silenced cells, migration was significantly diminished in SCC-9 LN-1 and A431 cells compared to scrambled control.

Cell viability was tested using MTT assay in the presence of 10% FBS, and we verified that SCC-9 and SCC-9 LN-1-agrin knockdown had a significant reduction in cell viability (Fig. 5A, n=3, One-way ANOVA, followed by Tukey’s test, p<0.001). In the A431 knockdown cells no significant difference was observed for agrin- or perlecan-siRNA, compared to the scrambled-siRNA (Fig. 5B).

The role of agrin and perlecan in cisplatin cell resistance

We sought to determine the cisplatin cell resistance in SCC-9, SCC-9 LN-1 and A431 when agrin or perlecan was silenced in these cell lines. It was observed that the siRNA-knockdown of agrin promoted a reduction in the cisplatin cell resistance in all cell lines used in this study: SCC-9 (2.4 fold), SCC-9 LN-1 (3.8 fold) and A431 (1.7 fold) (S3 Figure). On the other hand, when perlecan was silenced, no significant difference was observed in cisplatin cell resistance for SCC-9, SCC-9 LN-1 and A431 cell lines compared with scrambled (S3 Figure).

At a concentration of 10 μM of cisplatin, SCC-9, SCC-9 LN-1 and A431 cell lines showed a significant reduction in cell viability when agrin expression was silenced (Fig. 6A and B, n=3, ANOVA followed by Tukey’s test, p<0.05). A significant reduction in cell viability was also observed just in A431 perlecan-knockdown cells treated with 10 μM of cisplatin (Fig. 6C, n=3, ANOVA followed by Tukey’s test, p<0.05).
Discussion

Proteoglycans (PGs), essential macromolecules of the tumor microenvironment, have their expression altered during malignant transformation and tumor...
progression [9]. Agrin and perlecan are two of the major HSPG identified in the basement membrane, and their functional roles in modulation of cancer growth have been reviewed elsewhere [22]. In this study, we showed for the first time that agrin and perlecan are highly expressed in OSCCs, and the function of these proteins in oral cancer associated processes was investigated. Not only the expression of agrin and perlecan was shown to be higher in OSCC tissues compared to control tissues, but also their expression might be associated with different sites of origin, where higher expression of agrin was found in cell line originated from primary site (SCC-9), whereas higher expression of perlecan was found in cell line originated from metastatic site (SCC-9 LN-1). The spread of cancer cells from a primary tumor to form metastases at distant sites is a complex process that remains poorly defined [29], but it has been reported to involve detachment of cells from the tumor tissue, regulation of cell motility and invasion, proliferation and evasion through the lymphatic system or blood vessels [30]. Efforts have been made to elucidate tumor-related proteins that could influence the appearance of metastases in oral squamous cell carcinoma [31–33], which

Fig. 5. The role of agrin and perlecan in cell viability. The viability of SCC-9 (n=2, A) and SCC-9 LN-1 (n=3, B) was significantly reduced after siRNA-knockdown of agrin, but no difference in viability was observed in perlecan knockdown. The viability of A431 was not altered neither by agrin knockdown nor by perlecan knockdown (n=3, C) (One-way ANOVA followed by Tukey’s test, different letters indicate statistically difference at p<0.05).

doi:10.1371/journal.pone.0115004.g005

Fig. 6. Viability of SCC-9 LN-1 and A431 cell lines in 10 μM of cisplatin treatment. At 10 μM of cisplatin, the viability of SCC-9 (n=3, A), SCC-9 LN-1 (n=3, B) and A431 (n=3C) was significantly reduced when agrin was silenced. Only in A431 cell line the same result of decreasing in viability was observed for perlecan siRNA-knockdown (C) (One-way ANOVA followed by Tukey’s test, different letters indicate statistically difference at p<0.05).

doi:10.1371/journal.pone.0115004.g006
occur in about 40% of patients with oral cancer [34]. Therefore, the study of altered molecules in cell lines originated from distinct sites is essential to understand the molecular basis of this process.

GAGs polysaccharide chains are the main contributors to the proteoglycan functional properties and essential part of the matured proteoglycan molecules [35]. Besides, it was reported that glycans play a crucial role at various pathophysiological steps of cancer progression [36], especially by acting as coreceptors to stabilize growth-factor receptor signaling complexes and enhancing integrin-mediated cell adhesion, motility and intracellular signaling. The disruption of GAGs modification by heparanase was shown to facilitate tumor cell invasion [37] angiogenesis and metastasis [38]. In order to further understand the role of chondroitin sulfate modification in oral cancer, SCC-9 LN-1 cell lines were treated with chondroitinase and tested in adhesion and migration processes. Interestingly, when SCC-9 LN-1 cells were treated with chondroitinase, they had reduced ability to adhere to extracellular matrix proteins. It is important to mention that this event may be a result of the disruption of many cell surface chondroitin sulfate proteoglycans, such as syndecans, chondroitin sulfate proteoglycan 4, betaglycan, neuropilin-1, receptor protein tyrosine phosphatase, integrin and VEGFR-2, which were also previously demonstrated to be overexpressed in cancer [39].

It is well established that based upon their direct involvement in cell–cell and cell–ECM interactions, PGs have been strongly implicated in the regulation of cell movement [40]. However, how PGs actually affect this process is only partially understood and in some instances, controversial. In this study, we have demonstrated that agrin and perlecan play a role in the oral cancer cell movement by silencing agrin and perlecan, which promoted a strongly reduced in the ability of SCC-9 and SCC-9 LN-1 cell line to migrate and to adhere to matrigel.

Perlecan has been associated with the induction of cellular proliferation, differentiation and angiogenesis by interacting with a number of growth factors including FGFs 1, 2, 7, 9, and 18; hepatocyte growth factor, platelet derived growth factors-AA and -BB, and VEGF [14, 41]. Perlecan also exhibits adhesive [42] or anti-adhesive [43] properties presumably by differentially affecting surface receptors such as α2β1 integrin [44, 45]. Agrin is also able to interact with integrins [46], however there is still very limited acknowledgement on how agrin signals through the integrin receptors and how these interactions influence cell behavior.

Therapeutic PGs- and GAG-targeting modifications have been considered as anti-invasion and tumor-specific drug delivery potential approaches [47]. It was reported that both heparan sulfate and chondroitin sulfate modifications are able to interact with cisplatin and mediate entry-pathway [28, 48]. Platinum-based chemotherapy has been used for treating a wide variety of solid tumors, including lung, head and neck, ovarian, cervical, and testicular cancers for over three decades [49]. However, the emergence of drug resistance may limit the effectiveness of platinating agents in solid tumors [50–52], including OSCCs [53]. Recently, novel extracellular matrix cisplatin-resistant biomarkers from epithelial
ovarian carcinoma (EOC) were identified using secretome analysis from EOC cell lines [54]. In our study, we showed new evidences of increasing cisplatin-sensitivity by disrupting chondroitin sulfate modification, or reduction of agrin and perlecan proteins levels, suggesting it may have a potential target for therapeutic intervention.

In summary, we have identified a relevant role of agrin and perlecan in oral cancer cell adhesion, migration and cisplatin cell resistance, opening new perspectives for further investigations and targeting innovative and/or complementary therapeutic strategies.

Supporting Information

S1 Figure. Immunohistochemistry analysis of agrin in tissue microarray. Agrin showed higher expression in OSCC (n=47) compared with normal mucosa (n=10) (Mann-Whitney U test, p<0.0005). In lower panel, two representative figures show the higher expression of agrin in OSCC (B) compared with normal mucosa (A).

doi:10.1371/journal.pone.0115004.s001 (TIF)

S2 Figure. Confirmation by qRT-PCR of silencing of agrin in SCC-9 (A), SCC-9 LN-1 (B) and A431 (C) and perlecan in SCC-9 (D), SCC-9 LN-1 (E) and A431 (F). The data were normalized with the (glyceraldehyde-3-phosphate dehydrogenase gene was used as internal reference). Each bar represents mean ± SD of at least two independent experiments in triplicates.

doi:10.1371/journal.pone.0115004.s002 (TIF)

S3 Figure. The role of agrin and perlecan in cisplatin cell resistance. (A) SCC-9/ control (scrambled, IC50=14.57 µM), SCC-9/siRNA Agrin (IC50=6.02 µM) and SCC-9/siRNA Perlecan (IC50=12.68 µM) were treated with increasing concentrations of cisplatin (0–100 µM) for 48 h and the IC50 concentrations were calculated using dose response curves generated by GraphPad Prism software. (B) SCC-9 LN-1/control (scrambled, IC50=17.65 µM), SCC-9 LN-1/siRNA Agrin (IC50=4.662 µM) and SCC-9 LN-1/siRNA Perlecan (IC50=15.55 µM) were treated with increasing concentrations of cisplatin (0–100 µM) for 48 h and the IC50 concentrations were calculated using dose response curves generated by GraphPad Prism software. (C) A431/control (scrambled, IC50=6.59 µM), A431/siRNA Agrin (IC50=3.85 µM) and A431/siRNA Perlecan (IC50=6.65 µM) were treated with increasing concentrations of cisplatin (0–100 µM) for 48 h and the IC50 concentrations were calculated using dose-response curves generated by GraphPad Prism software.

doi:10.1371/journal.pone.0115004.s003 (TIF)

S1 Table. Clinicopathological characteristics of the patients with OSCC in the TMA.

doi:10.1371/journal.pone.0115004.s004 (XLSX)
S2 Table. Clinicopathological characteristics of the patients with OSCC used in the qRT-PCR analysis.  
doi:10.1371/journal.pone.0115004.s005 (XLSX)

Acknowledgments
We are thankful to Rafael Canevarolo from Laboratório Nacional de Biociências for suggesting some experiments.

Author Contributions
Conceived and designed the experiments: RK DCG AFPL. Performed the experiments: RK DCG CMC NC CEO SY FPF EG. Analyzed the data: RK CRM ARSS RDC AFPL. Contributed reagents/materials/analysis tools: EG ML RDC AFPL. Contributed to the writing of the manuscript: RK DCG NC RDC AFPL.

References
1. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371: 1695–1709.
2. Belcher R, Hayes K, Fedewa S, Chen AY (2014) Current treatment of head and neck squamous cell cancer. J Surg Oncol.
3. Mydlarz WK, Hennessey PT, Califano JA (2010) Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn 4: 53–65.
4. da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, et al. (2011) Advances and applications of oral cancer basic research. Oral Oncol 47: 783–791.
5. Pereira MC, Oliveira DT, Landman G, Kowalski LP (2007) Histologic subtypes of oral squamous cell carcinoma: prognostic relevance. J Can Dent Assoc 73: 339–344.
6. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82: 539–548.
7. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, et al. (2012) The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 11: M111 014647.
8. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, et al. (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277: 3890–3903.
9. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277: 3904–3923.
10. Iozzo RV, Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15: 1013–1031.
11. Edwards LJ (2012) Proteoglycans in prostate cancer. Nat Rev Urol 9: 196–206.
12. Tatrai P, Dudas J, Batmunkh E, Mathe M, Zalatnai A, et al. (2006) Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab Invest 86: 1149–1160.
13. Mundhenke C, Meyer K, Drew S, Friedl A (2002) Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 160: 185–194.
14. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, et al. (1998) Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102: 1599–1608.

15. Savore C, Zhang C, Muir C, Liu R, Wyrra J, et al. (2005) Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 22: 377–390.

16. Iozzo RV, Cohen IR, Grassel S, Murdoch AD (1994) The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302 (Pt 3): 625–639.

17. Noonan DM, Fulle A, Valente P, Cai S, Horigan E, et al. (1991) The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266: 22939–22947.

18. Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV (1994) Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Oral Pathol Med 33: 239–249.

19. Mishra M, Chandavarkar V, Naik VV, Kale AD (2013) An immunohistochemical study of basement membrane heparan sulfate proteoglycan (perlecan) in oral epithelial dysplasia and squamous cell carcinoma. J Oral Maxillofac Pathol 17: 31–35.

20. Ida-Yonemochi H, Ikarashi T, Nagata M, Hoshina H, Takagi R, et al. (2002) The basement membrane-type heparan sulfate proteoglycan (perlecan) in ameloblastomas: its intercellular localization in stellate reticulum-like foci and biosynthesis by tumor cells in culture. Virchows Arch 441: 165–173.

21. Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T (2004) Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 33: 87–95.

22. Iozzo RV, Zoeller JJ, Nystrom A (2009) Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol Cells 27: 503–513.

23. Winzen U, Cole GJ, Halfter W (2003) Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters. J Biol Chem 278: 30108–30114.

24. Somoracz A, Tatrai P, Horvath G, Kiss A, Kupcsulik P, et al. (2010) Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol 41: 1310–1319.

25. Batmunkh E, Tatrai P, Szabo E, Lodi C, Holczbauer A, et al. (2007) Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Hum Pathol 38: 1508–1515.

26. Agostini M, Almeida LY, Bastos DC, Ortega RM, Moreira FS, et al. (2014) The Fatty Acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. Mol Cancer Ther 13: 585–595.

27. Aragao AZ, Belloni M, Simabuco FM, Zanetti MR, Yokoo S, et al. (2012) Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration. PLoS One 7: e43521.

28. Silva H, Frezard F, Peterson EJ, Kabolizadeh P, Ryan JJ, et al. (2012) Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: differential cellular accumulation mechanisms for platinum. Mol Pharm 9: 1795–1802.

29. Terp MG, Lund RR, Jensen ON, Leth-Larsen R, Ditzel HJ (2012) Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Cancer Genomics Proteomics 9: 265–273.

30. Noguti J, De Moura CF, De Jesus GP, Da Silva VH, Hossaka TA, et al. (2012) Metastasis from oral cancer: an overview. Cancer Genomics Proteomics 9: 329–335.

31. O’Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, et al. (2005) Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24: 1244–1251.

32. Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, et al. (2011) Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res 10: 4935–4947.
33. Chai YD, Zhang L, Yang Y, Su T, Charugundla P, et al. (2014) Discovery of potential serum protein biomarkers for lymph-node metastasis in oral cancer. Head Neck.

34. Feller LJ (2012) Oral Squamous Cell Carcinoma: Epidemiology, Clinical Presentation and Treatment. Journal of Cancer Therapy 3: 263–268.

35. Afratis N, Gialeli C, Nikitovic D, Tsegendis T, Karousou E, et al. (2012) Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 279: 1177–1197.

36. Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526–542.

37. Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341–347.

38. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, et al. (2002) Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 99: 10031–10036.

39. Pantazaka E, Papadimitriou E (2014) Chondroitin sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration. Biochim Biophys Acta 1840: 2643–2650.

40. Cattaruzza S, Perris R (2005) Proteoglycan control of cell movement during wound healing and cancer spreading. Matrix Biol 24: 400–417.

41. Zhou Z, Wang J, Cao R, Morita H, Soininen R, et al. (2004) Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 64: 4699–4702.

42. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, et al. (1999) Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 18: 163–178.

43. Klein G, Conzelmann S, Beck S, Timpl R, Muller CA (1995) Perlecan in human bone marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol 14: 457–465.

44. Bix G, Iozzo RV (2005) Matrix revolutions: “tail” of basement-membrane components with angiostatic functions. Trends Cell Biol 15: 52–60.

45. Hayashi K, Madri JA, Yurchenco PD (1992) Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol 119: 945–959.

46. Martin PT, Sanes JR (1997) Integrins mediate adhesion to agrin and modulate agrin signaling. Development 124: 3909–3917.

47. Yip GW, Smollich M, Gotte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5: 2139–2148.

48. Zhang JS, Anraku M, Kadowaki D, Imai T, Suenaga A, et al. (2011) Spectroscopic studies of interactions of chondroitin sulfates with cisplatin. Carbohydr Res 346: 631–637.

49. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9–23.

50. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins J, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869–1883.

51. Dasari S, Bernard Tchounwou P (2014) Cisplatin in Cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.

52. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, et al. (2013) Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193.

53. Eberle KE, Sansing HA, Szaniszlo P, Resto VA, Berrier AL (2011) Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One 6: e21496.

54. Teng PN, Wang G, Hood BL, Conrads KA, Hamilton CA, et al. (2014) Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer 110: 123–132.